MET and neoplasm: Thus, efficacy studies using tumor model driven by both EGFR and c-Met revealed that the mechanisms of action of JNJ-671186372 included both inhibition of c-Met and EGFR pathways, as well as Fc effector function mediated upon binding of the anti-EGFR arm of the antibody; all contributed to in vivo efficacy.18